11/20
07:38 am
hoth
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
Medium
Report
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
11/4
08:19 am
hoth
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
Neutral
Report
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
10/29
12:43 pm
hoth
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
Medium
Report
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
10/16
08:32 am
hoth
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
High
Report
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.
10/15
06:44 am
hoth
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway [Yahoo! Finance]
Medium
Report
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway [Yahoo! Finance]
10/15
06:38 am
hoth
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
Low
Report
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
10/11
12:46 pm
hoth
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
Low
Report
Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "speculative buy" rating re-affirmed by analysts at Benchmark Co.. They now have a $3.00 price target on the stock.
9/17
07:59 am
hoth
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ [Yahoo! Finance]
High
Report
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ [Yahoo! Finance]
9/17
07:57 am
hoth
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
High
Report
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
9/6
12:14 pm
hoth
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient [Yahoo! Finance]
Medium
Report
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient [Yahoo! Finance]
9/5
10:32 am
hoth
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Medium
Report
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
9/5
08:09 am
hoth
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 [Yahoo! Finance]
High
Report
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 [Yahoo! Finance]
9/5
08:03 am
hoth
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
High
Report
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001